ID   EZH2_HUMAN              Reviewed;         746 AA.
AC   Q15910; B2RAQ1; B3KS30; B7Z1D6; B7Z7L6; Q15755; Q75MG3; Q92857;
AC   Q96FI6;
DT   15-JUL-1998, integrated into UniProtKB/Swiss-Prot.
DT   15-JUL-1998, sequence version 2.
DT   10-MAY-2017, entry version 170.
DE   RecName: Full=Histone-lysine N-methyltransferase EZH2 {ECO:0000305};
DE            EC=2.1.1.43 {ECO:0000269|PubMed:22323599};
DE   AltName: Full=ENX-1;
DE   AltName: Full=Enhancer of zeste homolog 2 {ECO:0000303|PubMed:28229514};
DE   AltName: Full=Lysine N-methyltransferase 6;
GN   Name=EZH2 {ECO:0000312|HGNC:HGNC:3527}; Synonyms=KMT6;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Brain;
RX   PubMed=8954776; DOI=10.1006/geno.1996.0588;
RA   Chen H., Rossier C., Antonarakis S.E.;
RT   "Cloning of a human homolog of the Drosophila enhancer of zeste gene
RT   (EZH2) that maps to chromosome 21q22.2.";
RL   Genomics 38:30-37(1996).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=9214638; DOI=10.1093/emboj/16.11.3219;
RA   Laible G., Wolf A., Dorn R., Reuter G., Nislow C., Lebersorger A.,
RA   Popkin D., Pillus L., Jenuwein T.;
RT   "Mammalian homologues of the Polycomb-group gene Enhancer of zeste
RT   mediate gene silencing in Drosophila heterochromatin and at S.
RT   cerevisiae telomeres.";
RL   EMBO J. 16:3219-3232(1997).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 3; 4 AND 5).
RC   TISSUE=Brain, and Testis;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=12853948; DOI=10.1038/nature01782;
RA   Hillier L.W., Fulton R.S., Fulton L.A., Graves T.A., Pepin K.H.,
RA   Wagner-McPherson C., Layman D., Maas J., Jaeger S., Walker R.,
RA   Wylie K., Sekhon M., Becker M.C., O'Laughlin M.D., Schaller M.E.,
RA   Fewell G.A., Delehaunty K.D., Miner T.L., Nash W.E., Cordes M., Du H.,
RA   Sun H., Edwards J., Bradshaw-Cordum H., Ali J., Andrews S., Isak A.,
RA   Vanbrunt A., Nguyen C., Du F., Lamar B., Courtney L., Kalicki J.,
RA   Ozersky P., Bielicki L., Scott K., Holmes A., Harkins R., Harris A.,
RA   Strong C.M., Hou S., Tomlinson C., Dauphin-Kohlberg S.,
RA   Kozlowicz-Reilly A., Leonard S., Rohlfing T., Rock S.M.,
RA   Tin-Wollam A.-M., Abbott A., Minx P., Maupin R., Strowmatt C.,
RA   Latreille P., Miller N., Johnson D., Murray J., Woessner J.P.,
RA   Wendl M.C., Yang S.-P., Schultz B.R., Wallis J.W., Spieth J.,
RA   Bieri T.A., Nelson J.O., Berkowicz N., Wohldmann P.E., Cook L.L.,
RA   Hickenbotham M.T., Eldred J., Williams D., Bedell J.A., Mardis E.R.,
RA   Clifton S.W., Chissoe S.L., Marra M.A., Raymond C., Haugen E.,
RA   Gillett W., Zhou Y., James R., Phelps K., Iadanoto S., Bubb K.,
RA   Simms E., Levy R., Clendenning J., Kaul R., Kent W.J., Furey T.S.,
RA   Baertsch R.A., Brent M.R., Keibler E., Flicek P., Bork P., Suyama M.,
RA   Bailey J.A., Portnoy M.E., Torrents D., Chinwalla A.T., Gish W.R.,
RA   Eddy S.R., McPherson J.D., Olson M.V., Eichler E.E., Green E.D.,
RA   Waterston R.H., Wilson R.K.;
RT   "The DNA sequence of human chromosome 7.";
RL   Nature 424:157-164(2003).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RC   TISSUE=Pancreas;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 134-746.
RX   PubMed=8649418; DOI=10.1128/MCB.16.6.3066;
RA   Hobert O., Jallal B., Ullrich A.;
RT   "Interaction of Vav with ENX-1, a putative transcriptional regulator
RT   of homeobox gene expression.";
RL   Mol. Cell. Biol. 16:3066-3073(1996).
RN   [8]
RP   INTERACTION WITH ATRX.
RX   PubMed=9499421; DOI=10.1093/hmg/7.4.679;
RA   Cardoso C., Timsit S., Villard L., Khrestchatisky M., Fontes M.,
RA   Colleaux L.;
RT   "Specific interaction between the XNP/ATR-X gene product and the SET
RT   domain of the human EZH2 protein.";
RL   Hum. Mol. Genet. 7:679-684(1998).
RN   [9]
RP   INTERACTION WITH EED, AND SUBCELLULAR LOCATION.
RX   PubMed=9584199; DOI=10.1128/MCB.18.6.3586;
RA   Sewalt R.G.A.B., van der Vlag J., Gunster M.J., Hamer K.M.,
RA   den Blaauwen J.L., Satijn D.P.E., Hendrix T., van Driel R., Otte A.P.;
RT   "Characterization of interactions between the mammalian polycomb-group
RT   proteins Enx1/EZH2 and EED suggests the existence of different
RT   mammalian polycomb-group protein complexes.";
RL   Mol. Cell. Biol. 18:3586-3595(1998).
RN   [10]
RP   INTERACTION WITH EED; HDAC1 AND HDAC2.
RX   PubMed=10581039; DOI=10.1038/70602;
RA   van der Vlag J., Otte A.P.;
RT   "Transcriptional repression mediated by the human polycomb-group
RT   protein EED involves histone deacetylation.";
RL   Nat. Genet. 23:474-478(1999).
RN   [11]
RP   INTERACTION WITH EED.
RX   PubMed=11158321; DOI=10.1128/MCB.21.4.1360-1369.2001;
RA   Satijn D.P.E., Hamer K.M., den Blaauwen J., Otte A.P.;
RT   "The polycomb group protein EED interacts with YY1, and both proteins
RT   induce neural tissue in Xenopus embryos.";
RL   Mol. Cell. Biol. 21:1360-1369(2001).
RN   [12]
RP   IDENTIFICATION BY MASS SPECTROMETRY, IDENTIFICATION IN THE PRC2
RP   COMPLEX WITH EED; RBBP4; RBBP7 AND SUZ12, METHYLTRANSFERASE ACTIVITY
RP   OF THE PRC2 COMPLEX, AND MUTAGENESIS OF CYS-588 AND HIS-689.
RX   PubMed=12435631; DOI=10.1101/gad.1035902;
RA   Kuzmichev A., Nishioka K., Erdjument-Bromage H., Tempst P.,
RA   Reinberg D.;
RT   "Histone methyltransferase activity associated with a human
RT   multiprotein complex containing the Enhancer of Zeste protein.";
RL   Genes Dev. 16:2893-2905(2002).
RN   [13]
RP   SUBCELLULAR LOCATION.
RX   PubMed=12101246; DOI=10.1128/MCB.22.15.5539-5553.2002;
RA   Sewalt R.G.A.B., Lachner M., Vargas M., Hamer K.M., den Blaauwen J.L.,
RA   Hendrix T., Melcher M., Schweizer D., Jenuwein T., Otte A.P.;
RT   "Selective interactions between vertebrate polycomb homologs and the
RT   SUV39H1 histone lysine methyltransferase suggest that histone H3-K9
RT   methylation contributes to chromosomal targeting of Polycomb group
RT   proteins.";
RL   Mol. Cell. Biol. 22:5539-5553(2002).
RN   [14]
RP   IDENTIFICATION BY MASS SPECTROMETRY, IDENTIFICATION IN THE PRC2
RP   COMPLEX WITH EED; RBBP4; RBBP7 AND SUZ12, AND METHYLTRANSFERASE
RP   ACTIVITY OF THE PRC2 COMPLEX.
RX   PubMed=12351676; DOI=10.1126/science.1076997;
RA   Cao R., Wang L., Wang H., Xia L., Erdjument-Bromage H., Tempst P.,
RA   Jones R.S., Zhang Y.;
RT   "Role of histone H3 lysine 27 methylation in Polycomb-group
RT   silencing.";
RL   Science 298:1039-1043(2002).
RN   [15]
RP   FUNCTION, SUBCELLULAR LOCATION, DEVELOPMENTAL STAGE, INDUCTION, AND
RP   TISSUE SPECIFICITY.
RX   PubMed=14532106; DOI=10.1093/emboj/cdg542;
RA   Bracken A.P., Pasini D., Capra M., Prosperini E., Colli E., Helin K.;
RT   "EZH2 is downstream of the pRB-E2F pathway, essential for
RT   proliferation and amplified in cancer.";
RL   EMBO J. 22:5323-5335(2003).
RN   [16]
RP   FUNCTION, INTERACTION WITH EED AND SUZ12, AND METHYLTRANSFERASE
RP   ACTIVITY OF THE PRC2 COMPLEX.
RX   PubMed=15385962; DOI=10.1038/sj.emboj.7600402;
RA   Pasini D., Bracken A.P., Jensen M.R., Lazzerini Denchi E., Helin K.;
RT   "Suz12 is essential for mouse development and for EZH2 histone
RT   methyltransferase activity.";
RL   EMBO J. 23:4061-4071(2004).
RN   [17]
RP   FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=15231737; DOI=10.1101/gad.1200204;
RA   Kirmizis A., Bartley S.M., Kuzmichev A., Margueron R., Reinberg D.,
RA   Green R., Farnham P.J.;
RT   "Silencing of human polycomb target genes is associated with
RT   methylation of histone H3 Lys 27.";
RL   Genes Dev. 18:1592-1605(2004).
RN   [18]
RP   CHARACTERIZATION OF THE PRC2 AND PRC3 COMPLEXES INCLUDING EED; EZH2;
RP   RBBP4; RBBP7 AND SUZ12, AND METHYLTRANSFERASE ACTIVITY OF THE PRC2 AND
RP   PRC3 COMPLEXES.
RX   PubMed=15099518; DOI=10.1016/S1097-2765(04)00185-6;
RA   Kuzmichev A., Jenuwein T., Tempst P., Reinberg D.;
RT   "Different EZH2-containing complexes target methylation of histone H1
RT   or nucleosomal histone H3.";
RL   Mol. Cell 14:183-193(2004).
RN   [19]
RP   FUNCTION, CHARACTERIZATION OF THE PRC2 COMPLEX INCLUDING AEBP2; EED;
RP   EZH2; RBBP4 AND SUZ12, AND METHYLTRANSFERASE ACTIVITY OF THE PRC2
RP   COMPLEX.
RX   PubMed=15225548; DOI=10.1016/j.molcel.2004.06.020;
RA   Cao R., Zhang Y.;
RT   "SUZ12 is required for both the histone methyltransferase activity and
RT   the silencing function of the EED-EZH2 complex.";
RL   Mol. Cell 15:57-67(2004).
RN   [20]
RP   DEVELOPMENTAL STAGE, AND INDUCTION.
RX   PubMed=15208672; DOI=10.1038/sj.onc.1207706;
RA   Tang X., Milyavsky M., Shats I., Erez N., Goldfinger N., Rotter V.;
RT   "Activated p53 suppresses the histone methyltransferase EZH2 gene.";
RL   Oncogene 23:5759-5769(2004).
RN   [21]
RP   FUNCTION IN RETINOIC ACID SIGNALING, AND INTERACTION WITH PRAME.
RX   PubMed=16179254; DOI=10.1016/j.cell.2005.07.003;
RA   Epping M.T., Wang L., Edel M.J., Carlee L., Hernandez M., Bernards R.;
RT   "The human tumor antigen PRAME is a dominant repressor of retinoic
RT   acid receptor signaling.";
RL   Cell 122:835-847(2005).
RN   [22]
RP   CHARACTERIZATION OF THE PRC4 COMPLEX INCLUDING EED; EZH2; RBBP4;
RP   RBBP7; SUZ12 AND SIRT1, AND METHYLTRANSFERASE ACTIVITY OF THE PRC4
RP   COMPLEX.
RX   PubMed=15684044; DOI=10.1073/pnas.0409875102;
RA   Kuzmichev A., Margueron R., Vaquero A., Preissner T.S., Scher M.,
RA   Kirmizis A., Ouyang X., Brockdorff N., Abate-Shen C., Farnham P.J.,
RA   Reinberg D.;
RT   "Composition and histone substrates of polycomb repressive group
RT   complexes change during cellular differentiation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 102:1859-1864(2005).
RN   [23]
RP   INTERACTION WITH EED AND SUZ12, PHOSPHORYLATION AT SER-21 BY AKT1, AND
RP   MUTAGENESIS OF SER-21.
RX   PubMed=16224021; DOI=10.1126/science.1118947;
RA   Cha T.-L., Zhou B.P., Xia W., Wu Y., Yang C.-C., Chen C.-T., Ping B.,
RA   Otte A.P., Hung M.-C.;
RT   "Akt-mediated phosphorylation of EZH2 suppresses methylation of lysine
RT   27 in histone H3.";
RL   Science 310:306-310(2005).
RN   [24]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-487, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=17081983; DOI=10.1016/j.cell.2006.09.026;
RA   Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P.,
RA   Mann M.;
RT   "Global, in vivo, and site-specific phosphorylation dynamics in
RT   signaling networks.";
RL   Cell 127:635-648(2006).
RN   [25]
RP   FUNCTION.
RX   PubMed=16618801; DOI=10.1101/gad.381706;
RA   Bracken A.P., Dietrich N., Pasini D., Hansen K.H., Helin K.;
RT   "Genome-wide mapping of Polycomb target genes unravels their roles in
RT   cell fate transitions.";
RL   Genes Dev. 20:1123-1136(2006).
RN   [26]
RP   METHYLTRANSFERASE ACTIVITY OF THE PRC2 COMPLEX.
RX   PubMed=16431907; DOI=10.1074/jbc.M513425200;
RA   Martin C., Cao R., Zhang Y.;
RT   "Substrate preferences of the EZH2 histone methyltransferase
RT   complex.";
RL   J. Biol. Chem. 281:8365-8370(2006).
RN   [27]
RP   FUNCTION.
RX   PubMed=16717091; DOI=10.1074/jbc.M603722200;
RA   Etchegaray J.P., Yang X., DeBruyne J.P., Peters A.H., Weaver D.R.,
RA   Jenuwein T., Reppert S.M.;
RT   "The polycomb group protein EZH2 is required for mammalian circadian
RT   clock function.";
RL   J. Biol. Chem. 281:21209-21215(2006).
RN   [28]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-487, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=16964243; DOI=10.1038/nbt1240;
RA   Beausoleil S.A., Villen J., Gerber S.A., Rush J., Gygi S.P.;
RT   "A probability-based approach for high-throughput protein
RT   phosphorylation analysis and site localization.";
RL   Nat. Biotechnol. 24:1285-1292(2006).
RN   [29]
RP   FUNCTION, AND INTERACTION OF THE PRC2 COMPLEX WITH DNMT1; DNMT3A AND
RP   DNMT3B.
RX   PubMed=16357870; DOI=10.1038/nature04431;
RA   Vire E., Brenner C., Deplus R., Blanchon L., Fraga M., Didelot C.,
RA   Morey L., Van Eynde A., Bernard D., Vanderwinden J.-M., Bollen M.,
RA   Esteller M., Di Croce L., de Launoit Y., Fuks F.;
RT   "The Polycomb group protein EZH2 directly controls DNA methylation.";
RL   Nature 439:871-874(2006).
RN   [30]
RP   ERRATUM.
RA   Vire E., Brenner C., Deplus R., Blanchon L., Fraga M., Didelot C.,
RA   Morey L., Van Eynde A., Bernard D., Vanderwinden J.-M., Bollen M.,
RA   Esteller M., Di Croce L., de Launoit Y., Fuks F.;
RL   Nature 446:824-824(2006).
RN   [31]
RP   FUNCTION.
RX   PubMed=16936726; DOI=10.1038/nsmb1142;
RA   Kim D.H., Villeneuve L.M., Morris K.V., Rossi J.J.;
RT   "Argonaute-1 directs siRNA-mediated transcriptional gene silencing in
RT   human cells.";
RL   Nat. Struct. Mol. Biol. 13:793-797(2006).
RN   [32]
RP   FUNCTION.
RX   PubMed=17210787; DOI=10.1101/gad.1499407;
RA   Kotake Y., Cao R., Viatour P., Sage J., Zhang Y., Xiong Y.;
RT   "pRB family proteins are required for H3K27 trimethylation and
RT   Polycomb repression complexes binding to and silencing p16INK4alpha
RT   tumor suppressor gene.";
RL   Genes Dev. 21:49-54(2007).
RN   [33]
RP   FUNCTION, DEVELOPMENTAL STAGE, AND INDUCTION.
RX   PubMed=17344414; DOI=10.1101/gad.415507;
RA   Bracken A.P., Kleine-Kohlbrecher D., Dietrich N., Pasini D.,
RA   Gargiulo G., Beekman C., Theilgaard-Moench K., Minucci S., Porse B.T.,
RA   Marine J.-C., Hansen K.H., Helin K.;
RT   "The Polycomb group proteins bind throughout the INK4A-ARF locus and
RT   are disassociated in senescent cells.";
RL   Genes Dev. 21:525-530(2007).
RN   [34]
RP   DE NOVO DNA METHYLATION OF PRC2 TARGET GENES.
RX   PubMed=17200670; DOI=10.1038/ng1950;
RA   Schlesinger Y., Straussman R., Keshet I., Farkash S., Hecht M.,
RA   Zimmerman J., Eden E., Yakhini Z., Ben-Shushan E., Reubinoff B.E.,
RA   Bergman Y., Simon I., Cedar H.;
RT   "Polycomb-mediated methylation on Lys27 of histone H3 pre-marks genes
RT   for de novo methylation in cancer.";
RL   Nat. Genet. 39:232-236(2007).
RN   [35]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-487, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18220336; DOI=10.1021/pr0705441;
RA   Cantin G.T., Yi W., Lu B., Park S.K., Xu T., Lee J.-D.,
RA   Yates J.R. III;
RT   "Combining protein-based IMAC, peptide-based IMAC, and MudPIT for
RT   efficient phosphoproteomic analysis.";
RL   J. Proteome Res. 7:1346-1351(2008).
RN   [36]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-487, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of
RT   the kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [37]
RP   FUNCTION, AND IDENTIFICATION IN THE PRC2/EED-EZH1 COMPLEX.
RX   PubMed=19026781; DOI=10.1016/j.molcel.2008.11.004;
RA   Margueron R., Li G., Sarma K., Blais A., Zavadil J., Woodcock C.L.,
RA   Dynlacht B.D., Reinberg D.;
RT   "Ezh1 and Ezh2 maintain repressive chromatin through different
RT   mechanisms.";
RL   Mol. Cell 32:503-518(2008).
RN   [38]
RP   IDENTIFICATION BY MASS SPECTROMETRY, IDENTIFICATION IN THE PRC2
RP   COMPLEX, AND METHYLTRANSFERASE ACTIVITY OF THE PRC2 COMPLEX.
RX   PubMed=18086877; DOI=10.1128/MCB.01589-07;
RA   Cao R., Wang H., He J., Erdjument-Bromage H., Tempst P., Zhang Y.;
RT   "Role of hPHF1 in H3K27 methylation and Hox gene silencing.";
RL   Mol. Cell. Biol. 28:1862-1872(2008).
RN   [39]
RP   FUNCTION, INTERACTION WITH EED; SUZ12 AND PHF1, METHYLTRANSFERASE
RP   ACTIVITY OF THE PRC2 COMPLEX, AND MUTAGENESIS OF HIS-689.
RX   PubMed=18285464; DOI=10.1128/MCB.02017-07;
RA   Sarma K., Margueron R., Ivanov A., Pirrotta V., Reinberg D.;
RT   "Ezh2 requires PHF1 to efficiently catalyze H3 lysine 27
RT   trimethylation in vivo.";
RL   Mol. Cell. Biol. 28:2718-2731(2008).
RN   [40]
RP   SUMOYLATION.
RX   PubMed=18628979; DOI=10.1371/journal.pone.0002704;
RA   Riising E.M., Boggio R., Chiocca S., Helin K., Pasini D.;
RT   "The polycomb repressive complex 2 is a potential target of SUMO
RT   modifications.";
RL   PLoS ONE 3:E2704-E2704(2008).
RN   [41]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-366; THR-367 AND
RP   THR-487, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [42]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J.,
RA   Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in
RT   a refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [43]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-487, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [44]
RP   FUNCTION, PHOSPHORYLATION AT THR-345 BY CDK1 AND CDK2, AND MUTAGENESIS
RP   OF THR-345.
RX   PubMed=20935635; DOI=10.1038/ncb2116;
RA   Chen S., Bohrer L.R., Rai A.N., Pan Y., Gan L., Zhou X., Bagchi A.,
RA   Simon J.A., Huang H.;
RT   "Cyclin-dependent kinases regulate epigenetic gene silencing through
RT   phosphorylation of EZH2.";
RL   Nat. Cell Biol. 12:1108-1114(2010).
RN   [45]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-487, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S.,
RA   Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full
RT   phosphorylation site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [46]
RP   INTERACTION WITH CDYL.
RX   PubMed=22009739; DOI=10.1074/jbc.M111.271064;
RA   Zhang Y., Yang X., Gui B., Xie G., Zhang D., Shang Y., Liang J.;
RT   "Corepressor protein CDYL functions as a molecular bridge between
RT   polycomb repressor complex 2 and repressive chromatin mark
RT   trimethylated histone lysine 27.";
RL   J. Biol. Chem. 286:42414-42425(2011).
RN   [47]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-487, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J.,
RA   Johansen P.T., Kratchmarova I., Kassem M., Mann M., Olsen J.V.,
RA   Blagoev B.;
RT   "System-wide temporal characterization of the proteome and
RT   phosphoproteome of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [48]
RP   FUNCTION.
RX   PubMed=23063525; DOI=10.1016/j.molcel.2012.09.004;
RA   Lee J.M., Lee J.S., Kim H., Kim K., Park H., Kim J.Y., Lee S.H.,
RA   Kim I.S., Kim J., Lee M., Chung C.H., Seo S.B., Yoon J.B., Ko E.,
RA   Noh D.Y., Kim K.I., Kim K.K., Baek S.H.;
RT   "EZH2 generates a methyl degron that is recognized by the
RT   DCAF1/DDB1/CUL4 E3 ubiquitin ligase complex.";
RL   Mol. Cell 48:572-586(2012).
RN   [49]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-76; THR-339; SER-363;
RP   THR-367 AND THR-487, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE
RP   SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [50]
RP   GLYCOSYLATION AT SER-75, MUTAGENESIS OF SER-75, AND FUNCTION.
RX   PubMed=24474760; DOI=10.1073/pnas.1323226111;
RA   Chu C.S., Lo P.W., Yeh Y.H., Hsu P.H., Peng S.H., Teng Y.C.,
RA   Kang M.L., Wong C.H., Juan L.J.;
RT   "O-GlcNAcylation regulates EZH2 protein stability and function.";
RL   Proc. Natl. Acad. Sci. U.S.A. 111:1355-1360(2014).
RN   [51]
RP   VARIANTS PHE-641; SER-641; ASN-641; HIS-641 AND CYS-641.
RX   PubMed=20081860; DOI=10.1038/ng.518;
RA   Morin R.D., Johnson N.A., Severson T.M., Mungall A.J., An J., Goya R.,
RA   Paul J.E., Boyle M., Woolcock B.W., Kuchenbauer F., Yap D.,
RA   Humphries R.K., Griffith O.L., Shah S., Zhu H., Kimbara M.,
RA   Shashkin P., Charlot J.F., Tcherpakov M., Corbett R., Tam A.,
RA   Varhol R., Smailus D., Moksa M., Zhao Y., Delaney A., Qian H.,
RA   Birol I., Schein J., Moore R., Holt R., Horsman D.E., Connors J.M.,
RA   Jones S., Aparicio S., Hirst M., Gascoyne R.D., Marra M.A.;
RT   "Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse
RT   large B-cell lymphomas of germinal-center origin.";
RL   Nat. Genet. 42:181-185(2010).
RN   [52]
RP   VARIANTS TRP-571; CYS-641; CYS-685 AND ASP-726, AND CHARACTERIZATION
RP   OF VARIANTS TRP-571; CYS-641; CYS-685 AND ASP-726.
RX   PubMed=20601953; DOI=10.1038/ng.621;
RA   Ernst T., Chase A.J., Score J., Hidalgo-Curtis C.E., Bryant C.,
RA   Jones A.V., Waghorn K., Zoi K., Ross F.M., Reiter A., Hochhaus A.,
RA   Drexler H.G., Duncombe A., Cervantes F., Oscier D., Boultwood J.,
RA   Grand F.H., Cross N.C.;
RT   "Inactivating mutations of the histone methyltransferase gene EZH2 in
RT   myeloid disorders.";
RL   Nat. Genet. 42:722-726(2010).
RN   [53]
RP   CHARACTERIZATION OF VARIANTS PHE-641 AND ASN-641.
RX   PubMed=21190999; DOI=10.1182/blood-2010-11-321208;
RA   Yap D.B., Chu J., Berg T., Schapira M., Cheng S.W., Moradian A.,
RA   Morin R.D., Mungall A.J., Meissner B., Boyle M., Marquez V.E.,
RA   Marra M.A., Gascoyne R.D., Humphries R.K., Arrowsmith C.H.,
RA   Morin G.B., Aparicio S.A.;
RT   "Somatic mutations at EZH2 Y641 act dominantly through a mechanism of
RT   selectively altered PRC2 catalytic activity, to increase H3K27
RT   trimethylation.";
RL   Blood 117:2451-2459(2011).
RN   [54]
RP   VARIANT HIS-685.
RX   PubMed=21828135; DOI=10.1182/blood-2010-10-311019;
RA   Jankowska A.M., Makishima H., Tiu R.V., Szpurka H., Huang Y.,
RA   Traina F., Visconte V., Sugimoto Y., Prince C., O'Keefe C., Hsi E.D.,
RA   List A., Sekeres M.A., Rao A., McDevitt M.A., Maciejewski J.P.;
RT   "Mutational spectrum analysis of chronic myelomonocytic leukemia
RT   includes genes associated with epigenetic regulation: UTX, EZH2, and
RT   DNMT3A.";
RL   Blood 118:3932-3941(2011).
RN   [55]
RP   VARIANTS WVS THR-134; GLU-156; ARG-279; MET-621; ASN-658; THR-677;
RP   CYS-679; LEU-690; 728-TYR--PRO-746 DEL AND CYS-736.
RX   PubMed=22190405; DOI=10.18632/oncotarget.385;
RG   Childhood Overgrowth Collaboration;
RA   Tatton-Brown K., Hanks S., Ruark E., Zachariou A., Duarte S.V.,
RA   Ramsay E., Snape K., Murray A., Perdeaux E.R., Seal S., Loveday C.,
RA   Banka S., Clericuzio C., Flinter F., Magee A., McConnell V.,
RA   Patton M., Raith W., Rankin J., Splitt M., Strenger V., Taylor C.,
RA   Wheeler P., Temple K.I., Cole T., Douglas J., Rahman N.;
RT   "Germline mutations in the oncogene EZH2 cause Weaver syndrome and
RT   increased human height.";
RL   Oncotarget 2:1127-1133(2011).
RN   [56]
RP   VARIANTS WVS SER-132; TYR-153 DEL AND TYR-689.
RX   PubMed=22177091; DOI=10.1016/j.ajhg.2011.11.018;
RA   Gibson W.T., Hood R.L., Zhan S.H., Bulman D.E., Fejes A.P., Moore R.,
RA   Mungall A.J., Eydoux P., Babul-Hirji R., An J., Marra M.A.,
RA   Chitayat D., Boycott K.M., Weaver D.D., Jones S.J.;
RT   "Mutations in EZH2 cause Weaver syndrome.";
RL   Am. J. Hum. Genet. 90:110-118(2012).
RN   [57]
RP   VARIANT GLY-677, CHARACTERIZATION OF VARIANTS ASN-641; CYS-641;
RP   HIS-641; PHE-641 AND GLY-677, FUNCTION, AND CATALYTIC ACTIVITY.
RX   PubMed=22323599; DOI=10.1073/pnas.1116418109;
RA   McCabe M.T., Graves A.P., Ganji G., Diaz E., Halsey W.S., Jiang Y.,
RA   Smitheman K.N., Ott H.M., Pappalardi M.B., Allen K.E., Chen S.B.,
RA   Della Pietra A. III, Dul E., Hughes A.M., Gilbert S.A., Thrall S.H.,
RA   Tummino P.J., Kruger R.G., Brandt M., Schwartz B., Creasy C.L.;
RT   "Mutation of A677 in histone methyltransferase EZH2 in human B-cell
RT   lymphoma promotes hypertrimethylation of histone H3 on lysine 27
RT   (H3K27).";
RL   Proc. Natl. Acad. Sci. U.S.A. 109:2989-2994(2012).
RN   [58]
RP   VARIANT WVS LYS-740.
RX   PubMed=23239504; DOI=10.1002/ajmg.a.35660;
RA   Al-Salem A., Alshammari M.J., Hassan H., Alazami A.M., Alkuraya F.S.;
RT   "Weaver syndrome and defective cortical development: a rare
RT   association.";
RL   Am. J. Med. Genet. A 161A:225-227(2013).
RN   [59]
RP   VARIANTS WVS CYS-133 AND CYS-679, CHARACTERIZATION OF VARIANTS WVS
RP   SER-132; CYS-133; TYR-153 DEL; CYS-679 AND TYR-689, VARIANT HIS-185,
RP   CHARACTERIZATION OF VARIANT HIS-185, AND MUTAGENESIS OF PHE-667.
RX   PubMed=26694085; DOI=10.1002/humu.22946;
RA   Cohen A.S., Yap D.B., Lewis M.E., Chijiwa C., Ramos-Arroyo M.A.,
RA   Tkachenko N., Milano V., Fradin M., McKinnon M.L., Townsend K.N.,
RA   Xu J., Van Allen M.I., Ross C.J., Dobyns W.B., Weaver D.D.,
RA   Gibson W.T.;
RT   "Weaver Syndrome-Associated EZH2 Protein Variants Show Impaired
RT   Histone Methyltransferase Function In Vitro.";
RL   Hum. Mutat. 37:301-307(2016).
RN   [60]
RP   INVOLVEMENT IN WVS.
RX   PubMed=28229514; DOI=10.1002/humu.23200;
RA   Imagawa E., Higashimoto K., Sakai Y., Numakura C., Okamoto N.,
RA   Matsunaga S., Ryo A., Sato Y., Sanefuji M., Ihara K., Takada Y.,
RA   Nishimura G., Saitsu H., Mizuguchi T., Miyatake S., Nakashima M.,
RA   Miyake N., Soejima H., Matsumoto N.;
RT   "Mutations in genes encoding polycomb repressive complex 2 subunits
RT   cause Weaver syndrome.";
RL   Hum. Mutat. 0:0-0(2017).
CC   -!- FUNCTION: Polycomb group (PcG) protein. Catalytic subunit of the
CC       PRC2/EED-EZH2 complex, which methylates 'Lys-9' (H3K9me) and 'Lys-
CC       27' (H3K27me) of histone H3, leading to transcriptional repression
CC       of the affected target gene. Able to mono-, di- and trimethylate
CC       'Lys-27' of histone H3 to form H3K27me1, H3K27me2 and H3K27me3,
CC       respectively. Displays a preference for substrates with less
CC       methylation, loses activity when progressively more methyl groups
CC       are incorporated into H3K27, H3K27me0 > H3K27me1 > H3K27me2
CC       (PubMed:22323599). Compared to EZH1-containing complexes, it is
CC       more abundant in embryonic stem cells and plays a major role in
CC       forming H3K27me3, which is required for embryonic stem cell
CC       identity and proper differentiation. The PRC2/EED-EZH2 complex may
CC       also serve as a recruiting platform for DNA methyltransferases,
CC       thereby linking two epigenetic repression systems. Genes repressed
CC       by the PRC2/EED-EZH2 complex include HOXC8, HOXA9, MYT1, CDKN2A
CC       and retinoic acid target genes. EZH2 can also methylate non-
CC       histone proteins such as the transcription factor GATA4 and the
CC       nuclear receptor RORA. Regulates the circadian clock via histone
CC       methylation at the promoter of the circadian genes. Essential for
CC       the CRY1/2-mediated repression of the transcriptional activation
CC       of PER1/2 by the CLOCK-ARNTL/BMAL1 heterodimer; involved in the di
CC       and trimethylation of 'Lys-27' of histone H3 on PER1/2 promoters
CC       which is necessary for the CRY1/2 proteins to inhibit
CC       transcription. {ECO:0000269|PubMed:14532106,
CC       ECO:0000269|PubMed:15225548, ECO:0000269|PubMed:15231737,
CC       ECO:0000269|PubMed:15385962, ECO:0000269|PubMed:16179254,
CC       ECO:0000269|PubMed:16357870, ECO:0000269|PubMed:16618801,
CC       ECO:0000269|PubMed:16717091, ECO:0000269|PubMed:16936726,
CC       ECO:0000269|PubMed:17210787, ECO:0000269|PubMed:17344414,
CC       ECO:0000269|PubMed:18285464, ECO:0000269|PubMed:19026781,
CC       ECO:0000269|PubMed:20935635, ECO:0000269|PubMed:22323599,
CC       ECO:0000269|PubMed:23063525, ECO:0000269|PubMed:24474760}.
CC   -!- CATALYTIC ACTIVITY: S-adenosyl-L-methionine + L-lysine-[histone] =
CC       S-adenosyl-L-homocysteine + N(6)-methyl-L-lysine-[histone].
CC       {ECO:0000269|PubMed:22323599}.
CC   -!- SUBUNIT: Binds ATRX via the SET domain (Probable). Component of
CC       the PRC2/EED-EZH2 complex, which includes EED, EZH2, SUZ12, RBBP4
CC       and RBBP7 and possibly AEBP2. The minimum components required for
CC       methyltransferase activity of the PRC2/EED-EZH2 complex are EED,
CC       EZH2 and SUZ12. The PRC2 complex may also interact with DNMT1,
CC       DNMT3A, DNMT3B and PHF1 via the EZH2 subunit and with SIRT1 via
CC       the SUZ12 subunit. Interacts with HDAC1 and HDAC2. Interacts with
CC       PRAME. Interacts with CDYL. Interacts with CLOCK, ARNTL/BMAL1 and
CC       CRY1 (By similarity). Interacts with DNMT3L; the interaction is
CC       direct (By similarity). {ECO:0000250|UniProtKB:Q61188,
CC       ECO:0000269|PubMed:10581039, ECO:0000269|PubMed:11158321,
CC       ECO:0000269|PubMed:12351676, ECO:0000269|PubMed:12435631,
CC       ECO:0000269|PubMed:15385962, ECO:0000269|PubMed:16179254,
CC       ECO:0000269|PubMed:16224021, ECO:0000269|PubMed:16357870,
CC       ECO:0000269|PubMed:18086877, ECO:0000269|PubMed:18285464,
CC       ECO:0000269|PubMed:19026781, ECO:0000269|PubMed:22009739,
CC       ECO:0000269|PubMed:9499421, ECO:0000269|PubMed:9584199,
CC       ECO:0000305}.
CC   -!- INTERACTION:
CC       Q8IXJ9:ASXL1; NbExp=6; IntAct=EBI-530054, EBI-1646500;
CC       P46100:ATRX; NbExp=2; IntAct=EBI-530054, EBI-396461;
CC       Q96MT8:CEP63; NbExp=3; IntAct=EBI-530054, EBI-741977;
CC       P26358:DNMT1; NbExp=8; IntAct=EBI-530054, EBI-719459;
CC       Q9Y6K1:DNMT3A; NbExp=6; IntAct=EBI-530054, EBI-923653;
CC       Q9UBC3:DNMT3B; NbExp=14; IntAct=EBI-530054, EBI-80125;
CC       Q9CWR8:Dnmt3l (xeno); NbExp=2; IntAct=EBI-530054, EBI-3043871;
CC       O75530:EED; NbExp=11; IntAct=EBI-530054, EBI-923794;
CC       Q9Y4K0:LOXL2; NbExp=2; IntAct=EBI-530054, EBI-7172227;
CC       O43189:PHF1; NbExp=4; IntAct=EBI-530054, EBI-530034;
CC       Q15156:PML-RAR; NbExp=8; IntAct=EBI-530054, EBI-867256;
CC       P10276:RARA; NbExp=2; IntAct=EBI-530054, EBI-413374;
CC       P40763:STAT3; NbExp=5; IntAct=EBI-530054, EBI-518675;
CC       O43463:SUV39H1; NbExp=2; IntAct=EBI-530054, EBI-349968;
CC   -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:12101246,
CC       ECO:0000269|PubMed:14532106, ECO:0000269|PubMed:15231737,
CC       ECO:0000269|PubMed:9584199}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=5;
CC       Name=1;
CC         IsoId=Q15910-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q15910-2; Sequence=VSP_038815;
CC       Name=3;
CC         IsoId=Q15910-3; Sequence=VSP_038814;
CC       Name=4;
CC         IsoId=Q15910-4; Sequence=VSP_038813;
CC         Note=No experimental confirmation available.;
CC       Name=5;
CC         IsoId=Q15910-5; Sequence=VSP_038813, VSP_038816;
CC         Note=No experimental confirmation available.;
CC   -!- TISSUE SPECIFICITY: Expressed in many tissues. Overexpressed in
CC       numerous tumor types including carcinomas of the breast, colon,
CC       larynx, lymphoma and testis. {ECO:0000269|PubMed:14532106}.
CC   -!- DEVELOPMENTAL STAGE: Expression decreases during senescence of
CC       embryonic fibroblasts (HEFs). Expression peaks at the G1/S phase
CC       boundary. {ECO:0000269|PubMed:14532106,
CC       ECO:0000269|PubMed:15208672, ECO:0000269|PubMed:17344414}.
CC   -!- INDUCTION: Expression is induced by E2F1, E2F2 and E2F3.
CC       Expression is reduced in cells subject to numerous types of stress
CC       including UV-, IR- and bleomycin-induced DNA damage and by
CC       activation of p53/TP53. {ECO:0000269|PubMed:14532106,
CC       ECO:0000269|PubMed:15208672, ECO:0000269|PubMed:17344414}.
CC   -!- PTM: Phosphorylated by AKT1. Phosphorylation by AKT1 reduces
CC       methyltransferase activity. Phosphorylation at Thr-345 by CDK1 and
CC       CDK2 promotes maintenance of H3K27me3 levels at EZH2-target loci,
CC       thus leading to epigenetic gene silencing.
CC       {ECO:0000269|PubMed:16224021, ECO:0000269|PubMed:20935635}.
CC   -!- PTM: Sumoylated. {ECO:0000269|PubMed:18628979}.
CC   -!- PTM: Glycosylated: O-GlcNAcylation at Ser-75 by OGT increases
CC       stability of EZH2 and facilitates the formation of H3K27me3 by the
CC       PRC2/EED-EZH2 complex. {ECO:0000269|PubMed:24474760}.
CC   -!- DISEASE: Weaver syndrome (WVS) [MIM:277590]: A syndrome of
CC       accelerated growth and osseous maturation, unusual craniofacial
CC       appearance, hoarse and low-pitched cry, and hypertonia with
CC       camptodactyly. Distinguishing features of Weaver syndrome include
CC       broad forehead and face, ocular hypertelorism, prominent wide
CC       philtrum, micrognathia, deep horizontal chin groove, and deep-set
CC       nails. In addition, carpal bone development is advanced over the
CC       rest of the hand. {ECO:0000269|PubMed:22177091,
CC       ECO:0000269|PubMed:22190405, ECO:0000269|PubMed:23239504,
CC       ECO:0000269|PubMed:26694085, ECO:0000269|PubMed:28229514}.
CC       Note=The disease is caused by mutations affecting the gene
CC       represented in this entry.
CC   -!- SIMILARITY: Belongs to the class V-like SAM-binding
CC       methyltransferase superfamily. Histone-lysine methyltransferase
CC       family. EZ subfamily. {ECO:0000255|PROSITE-ProRule:PRU00190}.
CC   -!- CAUTION: Two variants of the PRC2 complex have been described,
CC       termed PRC3 and PRC4. Each of the three complexes may include a
CC       different complement of EED isoforms, although the precise
CC       sequences of the isoforms in each complex have not been
CC       determined. The PRC2 and PRC4 complexes may also methylate 'Lys-
CC       26' of histone H1 in addition to 'Lys-27' of histone H3
CC       (PubMed:15099518 and PubMed:15684044), although other studies have
CC       demonstrated no methylation of 'Lys-26' of histone H1 by PRC2
CC       (PubMed:16431907). {ECO:0000305|PubMed:16431907}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAS07448.1; Type=Erroneous gene model prediction; Evidence={ECO:0000305};
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; X95653; CAA64955.1; -; mRNA.
DR   EMBL; U61145; AAC51520.1; -; mRNA.
DR   EMBL; AK302216; BAH13652.1; -; mRNA.
DR   EMBL; AK092676; BAG52592.1; -; mRNA.
DR   EMBL; AK293239; BAH11472.1; -; mRNA.
DR   EMBL; AK314291; BAG36948.1; -; mRNA.
DR   EMBL; AC006323; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC073140; AAS07448.1; ALT_SEQ; Genomic_DNA.
DR   EMBL; CH471146; EAW80067.1; -; Genomic_DNA.
DR   EMBL; CH471146; EAW80070.1; -; Genomic_DNA.
DR   EMBL; BC010858; AAH10858.1; -; mRNA.
DR   EMBL; U52965; AAC50591.1; -; Genomic_DNA.
DR   CCDS; CCDS56516.1; -. [Q15910-1]
DR   CCDS; CCDS56517.1; -. [Q15910-5]
DR   CCDS; CCDS56518.1; -. [Q15910-4]
DR   CCDS; CCDS5891.1; -. [Q15910-2]
DR   CCDS; CCDS5892.1; -. [Q15910-3]
DR   PIR; G02838; G02838.
DR   RefSeq; NP_001190176.1; NM_001203247.1. [Q15910-1]
DR   RefSeq; NP_001190177.1; NM_001203248.1. [Q15910-4]
DR   RefSeq; NP_001190178.1; NM_001203249.1. [Q15910-5]
DR   RefSeq; NP_004447.2; NM_004456.4. [Q15910-2]
DR   RefSeq; NP_694543.1; NM_152998.2. [Q15910-3]
DR   RefSeq; XP_011514186.1; XM_011515884.2. [Q15910-2]
DR   UniGene; Hs.444082; -.
DR   UniGene; Hs.732308; -.
DR   PDB; 2C6V; Model; -; A=508-734.
DR   PDB; 4MI0; X-ray; 2.00 A; A=520-746.
DR   PDB; 4MI5; X-ray; 2.00 A; A=521-746.
DR   PDB; 5GSA; X-ray; 2.49 A; C/D=40-68.
DR   PDB; 5H14; X-ray; 1.90 A; C/D=40-68.
DR   PDB; 5H15; X-ray; 2.27 A; C/D=40-68.
DR   PDB; 5H17; X-ray; 2.30 A; B=40-68.
DR   PDB; 5H19; X-ray; 1.90 A; B=40-68.
DR   PDB; 5H24; X-ray; 2.50 A; C/D=40-68.
DR   PDB; 5H25; X-ray; 2.88 A; C/D=40-68.
DR   PDB; 5HYN; X-ray; 2.95 A; A/F/K/Q=1-746.
DR   PDB; 5IJ7; X-ray; 2.62 A; A/B=429-487, A/B=511-746.
DR   PDB; 5IJ8; X-ray; 2.99 A; A/B=429-487, A/B=511-531, A/B=533-746.
DR   PDB; 5LS6; X-ray; 3.47 A; A/D/G/J=1-385, A/D/G/J=421-746.
DR   PDB; 5U5T; X-ray; 1.60 A; C/D=39-68.
DR   PDB; 5U62; X-ray; 1.90 A; C/D=39-68.
DR   PDBsum; 2C6V; -.
DR   PDBsum; 4MI0; -.
DR   PDBsum; 4MI5; -.
DR   PDBsum; 5GSA; -.
DR   PDBsum; 5H14; -.
DR   PDBsum; 5H15; -.
DR   PDBsum; 5H17; -.
DR   PDBsum; 5H19; -.
DR   PDBsum; 5H24; -.
DR   PDBsum; 5H25; -.
DR   PDBsum; 5HYN; -.
DR   PDBsum; 5IJ7; -.
DR   PDBsum; 5IJ8; -.
DR   PDBsum; 5LS6; -.
DR   PDBsum; 5U5T; -.
DR   PDBsum; 5U62; -.
DR   ProteinModelPortal; Q15910; -.
DR   SMR; Q15910; -.
DR   BioGrid; 108446; 277.
DR   DIP; DIP-34002N; -.
DR   IntAct; Q15910; 108.
DR   MINT; MINT-1371596; -.
DR   STRING; 9606.ENSP00000320147; -.
DR   BindingDB; Q15910; -.
DR   ChEMBL; CHEMBL2189110; -.
DR   GuidetoPHARMACOLOGY; 2654; -.
DR   iPTMnet; Q15910; -.
DR   PhosphoSitePlus; Q15910; -.
DR   BioMuta; EZH2; -.
DR   DMDM; 3334180; -.
DR   EPD; Q15910; -.
DR   MaxQB; Q15910; -.
DR   PaxDb; Q15910; -.
DR   PeptideAtlas; Q15910; -.
DR   PRIDE; Q15910; -.
DR   DNASU; 2146; -.
DR   Ensembl; ENST00000320356; ENSP00000320147; ENSG00000106462. [Q15910-2]
DR   Ensembl; ENST00000350995; ENSP00000223193; ENSG00000106462. [Q15910-3]
DR   Ensembl; ENST00000460911; ENSP00000419711; ENSG00000106462. [Q15910-1]
DR   Ensembl; ENST00000476773; ENSP00000419050; ENSG00000106462. [Q15910-5]
DR   Ensembl; ENST00000478654; ENSP00000417062; ENSG00000106462. [Q15910-5]
DR   Ensembl; ENST00000483967; ENSP00000419856; ENSG00000106462. [Q15910-4]
DR   GeneID; 2146; -.
DR   KEGG; hsa:2146; -.
DR   UCSC; uc003wfb.3; human. [Q15910-1]
DR   CTD; 2146; -.
DR   DisGeNET; 2146; -.
DR   GeneCards; EZH2; -.
DR   GeneReviews; EZH2; -.
DR   HGNC; HGNC:3527; EZH2.
DR   HPA; CAB009589; -.
DR   HPA; HPA029131; -.
DR   MalaCards; EZH2; -.
DR   MIM; 277590; phenotype.
DR   MIM; 601573; gene.
DR   neXtProt; NX_Q15910; -.
DR   OpenTargets; ENSG00000106462; -.
DR   Orphanet; 3447; Weaver syndrome.
DR   PharmGKB; PA27939; -.
DR   eggNOG; KOG1079; Eukaryota.
DR   eggNOG; COG2940; LUCA.
DR   GeneTree; ENSGT00760000119228; -.
DR   HOVERGEN; HBG002453; -.
DR   InParanoid; Q15910; -.
DR   KO; K11430; -.
DR   OMA; ITCKNVC; -.
DR   PhylomeDB; Q15910; -.
DR   TreeFam; TF314509; -.
DR   Reactome; R-HSA-212300; PRC2 methylates histones and DNA.
DR   Reactome; R-HSA-2559580; Oxidative Stress Induced Senescence.
DR   Reactome; R-HSA-3214841; PKMTs methylate histone lysines.
DR   Reactome; R-HSA-5617472; Activation of anterior HOX genes in hindbrain development during early embryogenesis.
DR   SignaLink; Q15910; -.
DR   SIGNOR; Q15910; -.
DR   ChiTaRS; EZH2; human.
DR   GeneWiki; EZH2; -.
DR   GenomeRNAi; 2146; -.
DR   PRO; PR:Q15910; -.
DR   Proteomes; UP000005640; Chromosome 7.
DR   Bgee; ENSG00000106462; -.
DR   CleanEx; HS_EZH2; -.
DR   ExpressionAtlas; Q15910; baseline and differential.
DR   Genevisible; Q15910; HS.
DR   GO; GO:0005737; C:cytoplasm; IEA:Ensembl.
DR   GO; GO:0035098; C:ESC/E(Z) complex; IDA:UniProtKB.
DR   GO; GO:0000790; C:nuclear chromatin; IDA:UniProtKB.
DR   GO; GO:0005654; C:nucleoplasm; TAS:Reactome.
DR   GO; GO:0005634; C:nucleus; IDA:MGI.
DR   GO; GO:0045120; C:pronucleus; IEA:Ensembl.
DR   GO; GO:0003682; F:chromatin binding; IDA:UniProtKB.
DR   GO; GO:0031490; F:chromatin DNA binding; IDA:UniProtKB.
DR   GO; GO:0001047; F:core promoter binding; ISS:UniProtKB.
DR   GO; GO:0003677; F:DNA binding; TAS:ProtInc.
DR   GO; GO:0042054; F:histone methyltransferase activity; IDA:MGI.
DR   GO; GO:0046976; F:histone methyltransferase activity (H3-K27 specific); IDA:UniProtKB.
DR   GO; GO:0018024; F:histone-lysine N-methyltransferase activity; IDA:MGI.
DR   GO; GO:0070878; F:primary miRNA binding; IEA:Ensembl.
DR   GO; GO:1990841; F:promoter-specific chromatin binding; IDA:UniProtKB.
DR   GO; GO:0016279; F:protein-lysine N-methyltransferase activity; TAS:Reactome.
DR   GO; GO:0043021; F:ribonucleoprotein complex binding; IEA:Ensembl.
DR   GO; GO:0000979; F:RNA polymerase II core promoter sequence-specific DNA binding; IEA:Ensembl.
DR   GO; GO:0014898; P:cardiac muscle hypertrophy in response to stress; IEA:Ensembl.
DR   GO; GO:0070301; P:cellular response to hydrogen peroxide; IEA:Ensembl.
DR   GO; GO:0035984; P:cellular response to trichostatin A; IEA:Ensembl.
DR   GO; GO:0021695; P:cerebellar cortex development; IEA:Ensembl.
DR   GO; GO:0006325; P:chromatin organization; TAS:ProtInc.
DR   GO; GO:0006306; P:DNA methylation; IEA:Ensembl.
DR   GO; GO:0070314; P:G1 to G0 transition; IEA:Ensembl.
DR   GO; GO:0036333; P:hepatocyte homeostasis; IEA:Ensembl.
DR   GO; GO:0021766; P:hippocampus development; IEA:Ensembl.
DR   GO; GO:0070734; P:histone H3-K27 methylation; IDA:UniProtKB.
DR   GO; GO:0098532; P:histone H3-K27 trimethylation; IEA:Ensembl.
DR   GO; GO:0016571; P:histone methylation; IMP:UniProtKB.
DR   GO; GO:0097421; P:liver regeneration; IEA:Ensembl.
DR   GO; GO:0045605; P:negative regulation of epidermal cell differentiation; IEA:Ensembl.
DR   GO; GO:2000134; P:negative regulation of G1/S transition of mitotic cell cycle; IEA:Ensembl.
DR   GO; GO:0045814; P:negative regulation of gene expression, epigenetic; IDA:UniProtKB.
DR   GO; GO:0048387; P:negative regulation of retinoic acid receptor signaling pathway; IMP:UniProtKB.
DR   GO; GO:0043433; P:negative regulation of sequence-specific DNA binding transcription factor activity; IEA:Ensembl.
DR   GO; GO:0051154; P:negative regulation of striated muscle cell differentiation; IEA:Ensembl.
DR   GO; GO:0034244; P:negative regulation of transcription elongation from RNA polymerase II promoter; IEA:Ensembl.
DR   GO; GO:0000122; P:negative regulation of transcription from RNA polymerase II promoter; IDA:UniProtKB.
DR   GO; GO:0045892; P:negative regulation of transcription, DNA-templated; IMP:UniProtKB.
DR   GO; GO:1900006; P:positive regulation of dendrite development; IEA:Ensembl.
DR   GO; GO:0010718; P:positive regulation of epithelial to mesenchymal transition; IDA:UniProtKB.
DR   GO; GO:0043547; P:positive regulation of GTPase activity; IDA:UniProtKB.
DR   GO; GO:0043406; P:positive regulation of MAP kinase activity; IDA:UniProtKB.
DR   GO; GO:0071902; P:positive regulation of protein serine/threonine kinase activity; IDA:UniProtKB.
DR   GO; GO:0071168; P:protein localization to chromatin; IEA:Ensembl.
DR   GO; GO:0042127; P:regulation of cell proliferation; IEA:Ensembl.
DR   GO; GO:0042752; P:regulation of circadian rhythm; IMP:UniProtKB.
DR   GO; GO:0014013; P:regulation of gliogenesis; IEA:Ensembl.
DR   GO; GO:0006355; P:regulation of transcription, DNA-templated; TAS:ProtInc.
DR   GO; GO:0032355; P:response to estradiol; IEA:Ensembl.
DR   GO; GO:1904772; P:response to tetrachloromethane; IEA:Ensembl.
DR   GO; GO:0048511; P:rhythmic process; IEA:UniProtKB-KW.
DR   GO; GO:0014834; P:skeletal muscle satellite cell maintenance involved in skeletal muscle regeneration; IEA:Ensembl.
DR   GO; GO:0006351; P:transcription, DNA-templated; IEA:UniProtKB-KW.
DR   InterPro; IPR026489; CXC_dom.
DR   InterPro; IPR021654; EZH1/EZH2.
DR   InterPro; IPR001005; SANT/Myb.
DR   InterPro; IPR001214; SET_dom.
DR   InterPro; IPR033467; Tesmin/TSO1-like_CXC.
DR   Pfam; PF11616; EZH2_WD-Binding; 1.
DR   Pfam; PF00856; SET; 1.
DR   SMART; SM01114; CXC; 1.
DR   SMART; SM00717; SANT; 2.
DR   SMART; SM00317; SET; 1.
DR   PROSITE; PS51633; CXC; 1.
DR   PROSITE; PS50280; SET; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Biological rhythms;
KW   Chromatin regulator; Complete proteome; Disease mutation;
KW   Glycoprotein; Methyltransferase; Nucleus; Phosphoprotein;
KW   Polymorphism; Reference proteome; Repressor; S-adenosyl-L-methionine;
KW   Transcription; Transcription regulation; Transferase; Ubl conjugation.
FT   CHAIN         1    746       Histone-lysine N-methyltransferase EZH2.
FT                                /FTId=PRO_0000213992.
FT   DOMAIN      503    605       CXC. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00970}.
FT   DOMAIN      612    727       SET. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00190}.
FT   REGION        1    340       Interaction with DNMT1, DNMT3A and
FT                                DNMT3B.
FT   REGION       39     68       Interaction with EED. {ECO:0000250}.
FT   REGION      329    522       Interaction with CDYL.
FT                                {ECO:0000269|PubMed:22009739}.
FT   COMPBIAS    523    605       Cys-rich.
FT   MOD_RES      21     21       Phosphoserine; by PKB/AKT1.
FT                                {ECO:0000269|PubMed:16224021}.
FT   MOD_RES      76     76       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES     339    339       Phosphothreonine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES     345    345       Phosphothreonine; by CDK1 and CDK2.
FT                                {ECO:0000269|PubMed:20935635}.
FT   MOD_RES     363    363       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES     366    366       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648}.
FT   MOD_RES     367    367       Phosphothreonine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES     487    487       Phosphothreonine.
FT                                {ECO:0000244|PubMed:16964243,
FT                                ECO:0000244|PubMed:17081983,
FT                                ECO:0000244|PubMed:18220336,
FT                                ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:18691976,
FT                                ECO:0000244|PubMed:19690332,
FT                                ECO:0000244|PubMed:20068231,
FT                                ECO:0000244|PubMed:21406692,
FT                                ECO:0000244|PubMed:23186163}.
FT   CARBOHYD     75     75       O-linked (GlcNAc) serine.
FT                                {ECO:0000269|PubMed:24474760}.
FT   VAR_SEQ      74     82       Missing (in isoform 4 and isoform 5).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_038813.
FT   VAR_SEQ      83    121       Missing (in isoform 3).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_038814.
FT   VAR_SEQ     297    298       HP -> HRKCNYS (in isoform 2).
FT                                {ECO:0000303|PubMed:15489334}.
FT                                /FTId=VSP_038815.
FT   VAR_SEQ     511    553       DGSSNHVYNYQPCDHPRQPCDSSCPCVIAQNFCEKFCQCSS
FT                                EC -> G (in isoform 5).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_038816.
FT   VARIANT     132    132       P -> S (in WVS; decreased histone
FT                                methyltransferase activity;
FT                                dbSNP:rs193921148).
FT                                {ECO:0000269|PubMed:22177091,
FT                                ECO:0000269|PubMed:26694085}.
FT                                /FTId=VAR_067595.
FT   VARIANT     133    133       Y -> C (in WVS; decreased histone
FT                                methyltransferase activity).
FT                                {ECO:0000269|PubMed:26694085}.
FT                                /FTId=VAR_078320.
FT   VARIANT     134    134       M -> T (in WVS).
FT                                {ECO:0000269|PubMed:22190405}.
FT                                /FTId=VAR_078321.
FT   VARIANT     153    153       Missing (in WVS; decreased histone
FT                                methyltransferase activity).
FT                                {ECO:0000269|PubMed:22177091,
FT                                ECO:0000269|PubMed:26694085}.
FT                                /FTId=VAR_067596.
FT   VARIANT     156    156       K -> E (in WVS).
FT                                {ECO:0000269|PubMed:22190405}.
FT                                /FTId=VAR_078322.
FT   VARIANT     185    185       D -> H (polymorhism; decreased histone
FT                                methyltransferase activity;
FT                                dbSNP:rs2302427).
FT                                {ECO:0000269|PubMed:26694085}.
FT                                /FTId=VAR_055795.
FT   VARIANT     279    279       H -> R (in WVS).
FT                                {ECO:0000269|PubMed:22190405}.
FT                                /FTId=VAR_078323.
FT   VARIANT     571    571       C -> W (found in a patient with
FT                                myelodysplastic syndrome and
FT                                myelodysplastic-myeloproliferative
FT                                neoplasms; somatic mutation; loss of
FT                                histone methyltransferase activity).
FT                                {ECO:0000269|PubMed:20601953}.
FT                                /FTId=VAR_078324.
FT   VARIANT     621    621       V -> M (in WVS; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:22190405}.
FT                                /FTId=VAR_078325.
FT   VARIANT     641    641       Y -> C (in a patient with diffuse large
FT                                B-cell lymphoma; somatic mutation;
FT                                changed substrate preferences; prefers
FT                                substrates with greater methylation
FT                                H3K27me0<me1<me2).
FT                                {ECO:0000269|PubMed:20081860,
FT                                ECO:0000269|PubMed:20601953,
FT                                ECO:0000269|PubMed:22323599}.
FT                                /FTId=VAR_067228.
FT   VARIANT     641    641       Y -> F (found in a patient with
FT                                follicular lymphoma; also in diffuse
FT                                large B-cell lymphoma; somatic mutation;
FT                                changed substrate preferences; prefers
FT                                substrates with greater methylation
FT                                H3K27me0<me1<me2; dbSNP:rs267601394).
FT                                {ECO:0000269|PubMed:20081860,
FT                                ECO:0000269|PubMed:22323599}.
FT                                /FTId=VAR_067229.
FT   VARIANT     641    641       Y -> H (found in patients with follicular
FT                                lymphoma; also in diffuse large B-cell
FT                                lymphoma; somatic mutation; changed
FT                                substrate preferences; prefers substrates
FT                                with greater methylation
FT                                H3K27me0<me1<me2; dbSNP:rs267601395).
FT                                {ECO:0000269|PubMed:20081860,
FT                                ECO:0000269|PubMed:22323599}.
FT                                /FTId=VAR_067230.
FT   VARIANT     641    641       Y -> N (found in patients with follicular
FT                                lymphoma; also in diffuse large B-cell
FT                                lymphoma; somatic mutation; changed
FT                                substrate preferences; prefers substrates
FT                                with greater methylation
FT                                H3K27me0<me1<me2).
FT                                {ECO:0000269|PubMed:20081860,
FT                                ECO:0000269|PubMed:22323599}.
FT                                /FTId=VAR_067231.
FT   VARIANT     641    641       Y -> S (found in patients with follicular
FT                                lymphoma; also in diffuse large B-cell
FT                                lymphoma; somatic mutation).
FT                                {ECO:0000269|PubMed:20081860}.
FT                                /FTId=VAR_067232.
FT   VARIANT     658    658       Y -> N (in WVS).
FT                                {ECO:0000269|PubMed:22190405}.
FT                                /FTId=VAR_078326.
FT   VARIANT     677    677       A -> G (found in a patient with B-cell
FT                                lymphoma; increased hypertrimethylation
FT                                of H3K27; changed substrate preferences;
FT                                confers biochemical activity independent
FT                                of H3K27 methylation state).
FT                                {ECO:0000269|PubMed:22323599}.
FT                                /FTId=VAR_078327.
FT   VARIANT     677    677       A -> T (in WVS).
FT                                {ECO:0000269|PubMed:22190405}.
FT                                /FTId=VAR_078328.
FT   VARIANT     679    679       R -> C (in WVS; decreased histone
FT                                methyltransferase activity).
FT                                {ECO:0000269|PubMed:22190405,
FT                                ECO:0000269|PubMed:26694085}.
FT                                /FTId=VAR_078329.
FT   VARIANT     685    685       R -> C (found in a patient with myeloid
FT                                disorders; somatic mutation; loss of
FT                                histone methyltransferase activity).
FT                                {ECO:0000269|PubMed:20601953}.
FT                                /FTId=VAR_078330.
FT   VARIANT     685    685       R -> H (in a patient with chronic
FT                                myelomonocytic leukemia).
FT                                {ECO:0000269|PubMed:21828135}.
FT                                /FTId=VAR_067233.
FT   VARIANT     689    689       H -> Y (in WVS; decreased histone
FT                                methyltransferase activity;
FT                                dbSNP:rs193921147).
FT                                {ECO:0000269|PubMed:22177091,
FT                                ECO:0000269|PubMed:26694085}.
FT                                /FTId=VAR_067597.
FT   VARIANT     690    690       S -> L (in WVS).
FT                                {ECO:0000269|PubMed:22190405}.
FT                                /FTId=VAR_078331.
FT   VARIANT     726    726       Y -> D (found in a patient with chronic
FT                                myelomonocytic leukemia; somatic
FT                                mutation; loss of histone
FT                                methyltransferase activity).
FT                                {ECO:0000269|PubMed:20601953}.
FT                                /FTId=VAR_078332.
FT   VARIANT     728    746       Missing (in WVS).
FT                                {ECO:0000269|PubMed:22190405}.
FT                                /FTId=VAR_078333.
FT   VARIANT     736    736       Y -> C (in WVS).
FT                                {ECO:0000269|PubMed:22190405}.
FT                                /FTId=VAR_078334.
FT   VARIANT     740    740       E -> K (in WVS; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:23239504}.
FT                                /FTId=VAR_078335.
FT   MUTAGEN      21     21       S->A: Enhances methyltransferase activity
FT                                towards 'Lys-27' of histone H3 and
FT                                abrogates phosphorylation by PKB/AKT1.
FT                                {ECO:0000269|PubMed:16224021}.
FT   MUTAGEN      21     21       S->D: Reduces methyltransferase activity
FT                                towards 'Lys-27' of histone H3 and
FT                                abrogates phosphorylation by PKB/AKT1.
FT                                {ECO:0000269|PubMed:16224021}.
FT   MUTAGEN      75     75       S->A: Reduced protein stability.
FT                                {ECO:0000269|PubMed:24474760}.
FT   MUTAGEN     345    345       T->A: Impaired CDK1- and CDK-2 mediated
FT                                phosphorylation and subsequent gene
FT                                silencing. Altered EZH2-mediated cell
FT                                proliferation and migration.
FT                                {ECO:0000269|PubMed:20935635}.
FT   MUTAGEN     588    588       C->Y: Strongly impairs methyltransferase
FT                                activity towards 'Lys-27' of histone H3.
FT                                {ECO:0000269|PubMed:12435631}.
FT   MUTAGEN     667    667       F->I: Strongly decreases histone
FT                                methyltransferase activity.
FT                                {ECO:0000269|PubMed:26694085}.
FT   MUTAGEN     689    689       H->A: Abrogates methyltransferase
FT                                activity. {ECO:0000269|PubMed:12435631,
FT                                ECO:0000269|PubMed:18285464}.
FT   CONFLICT     39     39       K -> N (in Ref. 3; BAG52592).
FT                                {ECO:0000305}.
FT   CONFLICT    224    224       F -> L (in Ref. 1; CAA64955).
FT                                {ECO:0000305}.
FT   CONFLICT    724    724       F -> V (in Ref. 1; CAA64955).
FT                                {ECO:0000305}.
FT   HELIX        44     62       {ECO:0000244|PDB:5U5T}.
FT   STRAND       82     87       {ECO:0000244|PDB:5HYN}.
FT   STRAND       94     97       {ECO:0000244|PDB:5HYN}.
FT   STRAND       99    101       {ECO:0000244|PDB:5HYN}.
FT   STRAND      126    129       {ECO:0000244|PDB:5HYN}.
FT   HELIX       135    138       {ECO:0000244|PDB:5HYN}.
FT   TURN        139    143       {ECO:0000244|PDB:5HYN}.
FT   HELIX       144    152       {ECO:0000244|PDB:5HYN}.
FT   TURN        153    155       {ECO:0000244|PDB:5HYN}.
FT   STRAND      161    163       {ECO:0000244|PDB:5LS6}.
FT   HELIX       168    181       {ECO:0000244|PDB:5HYN}.
FT   HELIX       221    230       {ECO:0000244|PDB:5HYN}.
FT   TURN        232    234       {ECO:0000244|PDB:5HYN}.
FT   HELIX       237    248       {ECO:0000244|PDB:5HYN}.
FT   STRAND      264    266       {ECO:0000244|PDB:5LS6}.
FT   HELIX       274    284       {ECO:0000244|PDB:5HYN}.
FT   TURN        287    289       {ECO:0000244|PDB:5HYN}.
FT   STRAND      291    293       {ECO:0000244|PDB:5HYN}.
FT   TURN        304    306       {ECO:0000244|PDB:5HYN}.
FT   HELIX       332    343       {ECO:0000244|PDB:5HYN}.
FT   HELIX       434    443       {ECO:0000244|PDB:5IJ7}.
FT   TURN        444    446       {ECO:0000244|PDB:5IJ7}.
FT   HELIX       451    458       {ECO:0000244|PDB:5IJ7}.
FT   STRAND      459    461       {ECO:0000244|PDB:5IJ7}.
FT   HELIX       463    471       {ECO:0000244|PDB:5IJ7}.
FT   STRAND      526    528       {ECO:0000244|PDB:5HYN}.
FT   HELIX       535    538       {ECO:0000244|PDB:4MI0}.
FT   STRAND      563    565       {ECO:0000244|PDB:4MI0}.
FT   HELIX       572    575       {ECO:0000244|PDB:4MI0}.
FT   TURN        582    584       {ECO:0000244|PDB:4MI0}.
FT   STRAND      587    589       {ECO:0000244|PDB:4MI0}.
FT   STRAND      590    592       {ECO:0000244|PDB:5LS6}.
FT   STRAND      594    596       {ECO:0000244|PDB:5HYN}.
FT   STRAND      600    603       {ECO:0000244|PDB:4MI0}.
FT   HELIX       605    608       {ECO:0000244|PDB:4MI0}.
FT   STRAND      614    618       {ECO:0000244|PDB:4MI0}.
FT   STRAND      620    630       {ECO:0000244|PDB:4MI0}.
FT   STRAND      637    640       {ECO:0000244|PDB:4MI0}.
FT   STRAND      643    647       {ECO:0000244|PDB:4MI0}.
FT   HELIX       648    656       {ECO:0000244|PDB:4MI0}.
FT   STRAND      666    668       {ECO:0000244|PDB:4MI0}.
FT   STRAND      670    676       {ECO:0000244|PDB:4MI0}.
FT   TURN        678    680       {ECO:0000244|PDB:4MI0}.
FT   HELIX       683    686       {ECO:0000244|PDB:4MI0}.
FT   STRAND      687    689       {ECO:0000244|PDB:4MI0}.
FT   STRAND      694    702       {ECO:0000244|PDB:4MI0}.
FT   STRAND      705    714       {ECO:0000244|PDB:4MI0}.
FT   STRAND      721    723       {ECO:0000244|PDB:5LS6}.
FT   HELIX       726    730       {ECO:0000244|PDB:5IJ7}.
SQ   SEQUENCE   746 AA;  85363 MW;  1B5029EB9D509BE5 CRC64;
     MGQTGKKSEK GPVCWRKRVK SEYMRLRQLK RFRRADEVKS MFSSNRQKIL ERTEILNQEW
     KQRRIQPVHI LTSVSSLRGT RECSVTSDLD FPTQVIPLKT LNAVASVPIM YSWSPLQQNF
     MVEDETVLHN IPYMGDEVLD QDGTFIEELI KNYDGKVHGD RECGFINDEI FVELVNALGQ
     YNDDDDDDDG DDPEEREEKQ KDLEDHRDDK ESRPPRKFPS DKIFEAISSM FPDKGTAEEL
     KEKYKELTEQ QLPGALPPEC TPNIDGPNAK SVQREQSLHS FHTLFCRRCF KYDCFLHPFH
     ATPNTYKRKN TETALDNKPC GPQCYQHLEG AKEFAAALTA ERIKTPPKRP GGRRRGRLPN
     NSSRPSTPTI NVLESKDTDS DREAGTETGG ENNDKEEEEK KDETSSSSEA NSRCQTPIKM
     KPNIEPPENV EWSGAEASMF RVLIGTYYDN FCAIARLIGT KTCRQVYEFR VKESSIIAPA
     PAEDVDTPPR KKKRKHRLWA AHCRKIQLKK DGSSNHVYNY QPCDHPRQPC DSSCPCVIAQ
     NFCEKFCQCS SECQNRFPGC RCKAQCNTKQ CPCYLAVREC DPDLCLTCGA ADHWDSKNVS
     CKNCSIQRGS KKHLLLAPSD VAGWGIFIKD PVQKNEFISE YCGEIISQDE ADRRGKVYDK
     YMCSFLFNLN NDFVVDATRK GNKIRFANHS VNPNCYAKVM MVNGDHRIGI FAKRAIQTGE
     ELFFDYRYSQ ADALKYVGIE REMEIP
//
